Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR-Mutant NSCLC with CNS Metastases: A Prospective Phase I/II Study

被引：0

作者：

Huang, M. J. ^{[1
,2
]}

Yu, M. ^{[1
,2
]}

Gong, Y. L. ^{[2
,3
]}

Li, Y. Y. ^{[2
]}

Liu, Y. M. ^{[2
]}

Peng, F. ^{[2
]}

Yu, Y. ^{[2
]}

Xiu, W. G. ^{[2
]}

Wang, Y. S. ^{[2
,4
]}

Zou, B. W. ^{[2
]}

Fan, H. ^{[5
]}

Zhong, L. Q. ^{[6
]}

Liu, T. Q. ^{[7
]}

Wang, X. F. ^{[8
]}

Xu, Y. ^{[2
]}

Zhou, L. ^{[2
]}

Lu, Y. ^{[1
,3
,9
]}

机构：

[1] Sichuan Univ, West China Hosp, Div Thorac Tumor Multimodal Treatment, Ctr Canc, Chengdu, Peoples R China

[2] Sichuan Univ, West China Hosp, Dept Med Oncol, Ctr Canc, Chengdu, Peoples R China

[3] Sichuan Univ, West China Hosp, Dept Radiat Oncol, Ctr Canc, Chengdu, Peoples R China

[4] Sichuan Univ, West China Hosp, Dept Clin Res, Chengdu, Peoples R China

[5] Peoples Hosp Leshan, Leshan, Peoples R China

[6] Yibin Second Peoples Hosp, Yibin, Peoples R China

[7] Hosp Shimian Cty, Yaan, Peoples R China

[8] Sichuan Sci City Hosp, Chengdu, Peoples R China

[9] Sichuan Univ, West China Hosp, Lab Clin Cell Therapy, Chengdu, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期

关键词：

aumolertinib; icotinib; central nervous system metastases;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA13.05

引用

下载

页码：S146 / S146

页数：1

共 50 条

[1] Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases
Huang, M.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S431 - S432
[2] Phase II study of erlotinib plus onartuzumab as first-line treatment for patients with MET-positive and EGFR-mutant NSCLC
Sakai, Hiroshi
Kishi, Kazuma
Seto, Takashi
Kozuki, Toshiyuki
Nishio, Makoto
Imamura, Fumio
Nokihara, Hiroshi
Satouchi, Miyako
Tahata, Takashi
Nakagawa, Kazuhiko
ANNALS OF ONCOLOGY, 2015, 26 : 82 - 82
[3] Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE)
Lin, G.
Chu, Q.
Huang, L.
Wu, L.
Yu, Y.
Liu, Z.
Huang, D.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S663 - S663
[4] CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC
Hui, C.
Wakelee, H. A.
Neal, J. W.
Ramchandran, K. J.
Das, M.
Nagpal, S.
Roy, M.
Huang, J.
Pollom, E.
Myall, N.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E110 - E110
[5] Safety and efficacy of osimertinib plus bevacizumab as first-line treatment in EGFR-mutant NSCLC with brain metastases: A dynamic ctDNA-guided study
Wei, Fang
An, Juan
Hua, Yichun
Ding, Xiaosheng
Sun, Shibin
Li, Xiaoyan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[6] Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)
Zhao, Hongyun
Yao, Wenxiu
Min, Xuhong
Gu, Kangsheng
Yu, Guohua
Zhang, Zhonghan
Cui, Jiuwei
Miao, Liyun
Zhang, Li
Yuan, Xia
Fang, Yong
Fu, Xiuhua
Hu, Chengping
Zhu, Xiaoli
Fan, Yun
Yu, Qitao
Wu, Gang
Jiang, Ou
Du, Xiuping
Liu, Jiwei
Gu, Wei
Hou, Zhiguo
Wang, Quanren
Zheng, Rongrong
Zhou, Xianfeng
Zhang, Li
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1533 - 1546
[7] Outcomes in patients with EGFR-mutant locally advanced or metastatic NSCLC co-mutations receiving aumolertinib as first-line treatment: A retrospective study
Cun, F. S.
Zhang, H.
ANNALS OF ONCOLOGY, 2022, 33 : S1586 - S1586
[8] Study on the Molecular Markers of Resistance in the First-line Treatment of NSCLC with EGFR Positive by Aumolertinib
Duan, J. C.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S652 - S652
[9] OSIMERTINIB MAY BE AN EFFECTIVE FIRST-LINE THERAPY IN EGFR-MUTANT NSCLC
不详
CANCER DISCOVERY, 2017, 7 (10) : 1061 - 1061
[10] Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue
Piotrowska, Zofia
Hata, Aaron N.
CLINICAL CANCER RESEARCH, 2020, 26 (11) : 2441 - 2443

← 1 2 3 4 5 →